The CU Healthcare Innovation Fund, established in 2019, operates as a corporate venture capital arm of the University of Colorado Anschutz Medical Campus in Aurora, Colorado. With a capital of $50 million, the fund focuses on investing in companies that have formed significant partnerships with the campus's institutions. Its investment strategy encompasses various sectors within healthcare, including digital health, therapeutics, and medical devices. The fund aims to support innovations that can enhance healthcare delivery and outcomes.
410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.
Jupiter Bioventures
Venture Round in 2024
Jupiter Bioventures is a venture builder firm dedicated to supporting early-stage therapeutic projects. The company aims to de-risk these initiatives by carefully evaluating opportunities against specific investment criteria. By providing small amounts of seed capital, Jupiter Bioventures enables founders to cultivate their projects and advance their development. Through its focused approach, the firm plays a crucial role in fostering innovation in the therapeutic sector.
Foresight Diagnostics
Series B in 2024
Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.
Clarapath
Series B in 2024
Clarapath, Inc. is a medical robotics company that specializes in automating laboratory processes for digital pathology applications. Founded in 2011 and headquartered in New York, the company has developed Section Star, an automated device that streamlines microtomy through a tape transfer method. Clarapath provides a range of services, including routine histology, pathology consultation, whole slide imaging, quantitative image analysis, and long-term data management. Its anatomic pathology laboratory caters to both human and animal digital pathology needs, serving academic researchers and clinical laboratories. The company aims to enhance the quality and efficiency of lab medicine while reducing costs and labor-related delays. By integrating its technologies, Clarapath facilitates real-time access to tissue samples, thereby standardizing and simplifying the histology process and improving safety and throughput in laboratory settings.
Q32 Bio
Post in 2024
Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.
Vytyl Health Management
Series A in 2024
Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.
Foresight Diagnostics
Series B in 2023
Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.
ClinOne
Series A in 2023
ClinOne, Inc. is a clinical trial management solution that develops a mobile application designed to enhance communication and streamline workflow among researchers, investigators, and research staff. Founded in 2013 and based in Greenwood Village, Colorado, ClinOne’s platform provides web and mobile access to essential clinical trial information, facilitating better interaction and engagement between researchers and patients. The application aims to improve clinical trial enrollment, retention, compliance at research sites, and overall patient experience. ClinOne offers a comprehensive suite of mobile technologies that centralize research efforts and deliver pertinent trial content to participants. Its clientele includes notable organizations such as Array Biopharma, Genentech, Actelion, Takeda, and Boston Scientific.
CodaMetrix
Series A in 2023
CodaMetrix is a developer of an AI-powered platform focused on automating healthcare revenue cycle management and medical coding. The platform utilizes machine learning, deep learning, and natural language processing to accurately translate clinical notes into billing and diagnostic codes. This automation not only meets coding requirements but also significantly reduces the workload for human coders. By continuously learning from clinical evidence within electronic health records and drawing from a comprehensive library of data points from national health systems, CodaMetrix enhances coding efficiency and quality, ultimately allowing healthcare providers to optimize their operations.
Sensorium Therapeutics
Venture Round in 2022
Sensorium Therapeutics is a drug discovery platform based in Boston, Massachusetts, that focuses on developing novel FDA-approved psychoactive medicines. Founded in 2021, the company utilizes an artificial intelligence product engine to discover and develop drugs targeting central nervous system diseases. By integrating historical human efficacy data from natural compounds, Sensorium Therapeutics aims to create new medicines characterized by innovative pharmacology and improved clinical success rates. This approach enables pharmaceutical companies to enhance their drug development processes effectively.
Carta Healthcare
Series B in 2022
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Eon Health
Series A in 2022
Eon Health is a healthcare technology company based in Denver, Colorado, that specializes in software solutions designed to enhance complex patient management. Founded in 2015 as Matrix Analytics and rebranded in 2018, Eon Health focuses on improving the way healthcare data is gathered, curated, and shared among professionals. Its EonDirect software platform integrates with hospitals' existing electronic health record (EHR) and electronic medical record (EMR) systems, providing an online dashboard that aids healthcare providers in diagnosing and treating complex diseases. The company currently collaborates with 31 hospitals to manage over 12,000 patients, ensuring that critical data is accessible to the right professionals at the right time.
Reimagine Care
Series A in 2022
Reimagine Care is a healthcare company focused on enhancing community-based oncology care through technology-enabled services. Established in 2020 and based in Nashville, Tennessee, the company seeks to improve the affordability, accessibility, and patient-centricity of cancer care. By collaborating with healthcare systems and independent oncology practices, Reimagine Care supports value-based oncology care delivery. Their approach involves providing the necessary personnel, processes, and a comprehensive technology platform that facilitates the effective and scalable delivery of high-quality cancer care at various locations, including patients' homes. This model aims to enable patients to receive treatment and supportive care in a more convenient and cost-effective manner.
GoCheck
Venture Round in 2021
GoCheck, formerly known as Gobiquity, Inc., is a technology company based in Aliso Viejo, California, that specializes in mobile health applications aimed at the early detection and prevention of eye diseases in children. The company's flagship product, GoCheck Kids, is a smartphone app designed for the screening of amblyopia risk factors, adhering to guidelines established by the American Association for Pediatric Ophthalmology and Strabismus. With a focus on affordability, GoCheck Kids reduces the cost of vision screening by over 60% by utilizing the manufacturing capabilities of smartphones. The app is FDA-registered and CE certified, and it is currently utilized by over 6,500 pediatric teams across the U.S. and Europe. By facilitating early detection, GoCheck aims to combat vision impairment, a leading disabling condition among children, which can severely impact learning and overall health outcomes.
Cured
Series A in 2021
Cured, Inc. is a healthcare technology company that specializes in developing digital marketing tools and customer relationship management platforms for the healthcare sector. Founded in 2018 and headquartered in San Francisco, with additional offices in Chicago and Denver, Cured offers solutions that connect health systems and organizations to patients and their families. The company's cloud-based platform focuses on network management, patient marketing, and customer experience, providing design and product development services that address the unique challenges faced by healthcare and life sciences organizations. By leveraging modern business tools and integrating contact centers with electronic medical records, Cured enables clients to enhance brand awareness, improve patient satisfaction, and create engaging digital experiences that foster better healthcare behaviors and outcomes.
Babyscripts
Series B in 2021
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.
Carta Healthcare
Series A in 2021
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Riva Health
Venture Round in 2021
Riva Health is focused on advancing cardiovascular healthcare through innovative technology. The company has developed a digital therapeutics application that enables users to monitor hypertension using their smartphone's camera and graphics processing capabilities. By employing a technique known as photoplethysmography, the app allows individuals to measure their blood pressure conveniently from home, addressing a significant health concern given that heart disease is the leading cause of mortality in the United States. Co-founded by Dag Kittlaus and Tuhin Sinha, Riva Health aims to enhance the management of cardiovascular conditions through accessible and user-friendly solutions.
Babyscripts
Venture Round in 2020
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.
AristaMD
Series B in 2020
AristaMD is a digital health company based in La Jolla, California, founded in 2013. It specializes in enhancing the specialty referral process through its eConsult platform. This platform equips primary care providers with clinical workup checklists and enables electronic consultations with specialists. AristaMD's solution allows payers and providers to initiate specialist eConsults using their own specialists or those from AristaMD’s board-certified panel. The platform facilitates the transmission of patient clinical notes, history, lab results, and images, fostering collaboration on care plans within hours. This approach aims to improve patient outcomes by providing timely access to specialty care and reducing referral wait times.
ClinOne
Series A in 2020
ClinOne, Inc. is a clinical trial management solution that develops a mobile application designed to enhance communication and streamline workflow among researchers, investigators, and research staff. Founded in 2013 and based in Greenwood Village, Colorado, ClinOne’s platform provides web and mobile access to essential clinical trial information, facilitating better interaction and engagement between researchers and patients. The application aims to improve clinical trial enrollment, retention, compliance at research sites, and overall patient experience. ClinOne offers a comprehensive suite of mobile technologies that centralize research efforts and deliver pertinent trial content to participants. Its clientele includes notable organizations such as Array Biopharma, Genentech, Actelion, Takeda, and Boston Scientific.
IMTherapeutics
Series A in 2019
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
Carta Healthcare
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.